Cellartis Y30010 DEF-CS 500 Culture System,人iPS细胞培养

 华雅旗下红荣微再授权代理（上海）TAKARA CellArtis，Rubicon产品 

1500 1904 520。红荣微再-客服:  经销商专员

DEF-CS 500 Culture System,人iPS细胞培养

DEF-CS是单个干细胞基因操作的理想选择，和目前市场上知名的相关产品不同的是，DEF-CS在设计上就是支持单细胞生长的。

英文名称：Cellartis® DEF-CS™ 500 Culture System

中文名称：Cellartis® DEF-CS™ 500人iPS细胞无血清培养系统

特点：成分确定 无血清 无饲养层 完全培养基

用途：iPS细胞大规模培养，单细胞培养，转染和Scaffold接种。

保存：基础培养基和包被剂2-8°C，添加剂-20°C

DEF-CS系统是一个强大的培养系统，用于在无饲养层和确定环境下GX扩增人多能诱导干细胞（iPS）。该系统能够实现稳定的生长速率，适合传统iPS细胞培养，细胞批量生产和单细胞培养。用此培养系统生长的细胞保持未分化状态，不会有可检测的背景分化，无需细胞选择。酶法传代的单细胞可用于单细胞相关应用，包括高通量筛选，转染和支架接种（scaffold seeding）。

☆ 成分确定、无血清、无饲养层培养

☆ All-In-One型：培养液+添加剂+包被剂

☆ 细胞单层生长，可进行单细胞传代

☆ 维持未分化状态，无需筛选分化细胞

☆ 单个干细胞基因操作实验的理想选择

产品应用

·放大和大规模生产人类iPS细胞

·人类iPS细胞的单细胞培养

·转染和重编程

·高通量筛选

·组织工程（支架接种）

DEF-CS是单个干细胞基因操作的理想选择

Human iPS和Human ES增殖用培养基(DEF-CS Culture System, all-in-one format)

作为一款高端创新型的产品，Cellartis DEF-CS培养系统使得单细胞干细胞操作成为常规的操作。该产品是专门针对人类诱导干细胞（hiPS）和人类胚胎干细胞（hES）研发的GX率增殖用培养基产品体系。该产品系统为all-in-one型，包括了所有组分，客户不需要另外求购组分。该产品是成分确定的培养基产品，而且不需要饲养层。DEF-CS既可以实现单细胞培养，也可以用于传统的iPS培养模式以及大规模干细胞增殖。在使用DEF-CS培养基增殖干细胞时，几乎没有背景分化的问题，这使得细胞筛选不再必需。作为一款创新产品，利用DEF-CS培养干细胞时，可以使用酶消化法（enzymatic passaging）实现需要单细胞操作，这一特点十分有利于高通量细胞鉴别筛选（high-throughput screening）、转染（transfection）、支架接种（scaffold seeding）等。

Cellartis DEF-CS 500 Culture System 组份

培养系统包括基础培养基、包被剂和添加剂

Cellartis DEF-CS 500 Culture System (Cat. No. Y30010)

500 ml Cellartis DEF-CS 500 Basal Medium (Cat. No. Y30011; not sold separay)

4 ml Cellartis DEF-CS 500 COAT-1 (Cat. No. Y30012)

Cellartis DEF-CS 500 Additives (Cat. No. Y30016)：

o 2 x 750 µl DEF-CS GF-1

o 500 µl DEF-CS GF-2

o 200 µl DEF-CS GF-3

需要自行准备试剂：PBS（含钙镁和不含钙镁），TrypLE选择酶（无酚红）

PBS Dulbecco's with Ca2+ & Mg2+ (D-PBS +/+)

PBS Dulbecco's w/o Ca2+ & Mg2+ (D-PBS –/–)

TrypLE Select Enzyme (1X), no phenol red

手机1500 1904 520 红荣微再-客服  经销商专员

DEF-CS 500 Culture System,人iPS细胞培养

培养性能

单细胞传代

Human induced pluripotent stem (iPS) cells can be passaged as single cells in the Cellartis DEF-CS Culture System. A single GFP-actin iPS cell was isolated and placed in the well of a culture dish. Twenty-four hours after seeding, morphology was assessed by fluorescence microscopy at 20x (Panel A) and 40x (Panel B) magnification. Sixteen days later, the single GFP-actin iPS cell had proliferated into numerous cells as evidenced by microscopic observation at 4x (Panel C), 10x (Panel D), 20x (Panel E), and 40x (Panel F) magnification.

扩增潜力

Expansion potential of a characterized working bank of human induced pluripotent stem (iPS) cells in the Cellartis DEF-CS Culture System. The Cellartis DEF-CS Culture System can produce 2 x 109 human iPS cells within 4 passages (18–20 days) from frozen cells (2.0–2.5 x 106 cells).

多能干性维持

Human pluripotent stem cells remain undifferentiated when cultured in the Cellartis DEF-CS Culture System. Human iPS cells cultured for 23 passages in the Cellartis DEF-CS Culture System were characterized by Oct-4 staining (A) and nuclear staining (B).

参考文献：

1. Sivertsson, Louise, et al. "Hepatic differentiation and maturation of human embryonic stem cells cultured in a perfused     three-dimensional bioreactor." Stem cells and development 22.4 (2012): 581-594.

2. Hanson, Charles, et al. "Transplantation of human embryonic stem cells onto a partially wounded human cornea in     vitro." Acta ophthalmologica 91.2 (2013): 127-130.

3. Norrman, Karin, et al. "Distinct gene expression signatures in human embryonic stem cells differentiated towards definitive endoderm at single-cell level." Methods 59.1 (2013): 59-70.

4. Ulvestad, Maria, et al. "Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells." Biochemical pharmacology 86.5 (2013): 691-702.

5. Ramirez JM, et al. Side scatter intensity is highly heterogeneous in undifferentiated pluripotent stem cells and predicts clonogenic self-renewal. Stem Cells Dev.2013 Jun 15;22(12):1851-1860.

6. Borestrom, Cecilia, et al. “Footprint-free human induced pluripotent stem cells from articular cartilage with redifferentiation capacity: A first step toward a clinical-grade cell source.” Stem Cells Trans. Med. (2014) 3, 433-447.

7. Kia, Richard, et al. "MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity." Toxicological Sciences (2014): kfu269.

8. Valton, Julien, et al. "Efficient strategies for TALEN-mediated genome editing in mammalian cell lines." Methods 69.2 (2014): 151-170.

9. Zandén, Carl, et al. "Stem cell responses to plasma surface modified electrospun polyurethane scaffolds." Nanomedicine: Nanotechnology, Biology and Medicine 10.5 (2014): 949-958.

10. Asplund, Annika, et al. “One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying? Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells” Stem Cell Rev and Rep (2015)

华雅再生医学旗舰公司：红荣微再（上海）生物工程技术有限公司主营细胞ZL和JZYL等产品，2018年与TAKARA继续合作，授权代理（上海）其旗下Cellartis干细胞研究制品和Rubicon单细胞文库构建试剂。Cellartis公司位于瑞典，拥有iPS细胞等干细胞分化为肝细胞及脏器细胞的分化诱导技术和ES细胞，ips细胞，分化细胞等干细胞相关产品。

手机1500 1904 520 红荣微再-客服  经销商专员